OBJECTIVES: To establish whether symptomatic seroconverting illness in HIV infected people is associated with more rapid development of neurological impairment. METHODS: 166 HIV infected subjects with a known date of HIV infection enrolled in a longitudinal study of neurocognitive function were stratified by whether or not they had experienced a symptomatic serconverting illness. RESULTS: 29 of 166 (17.5%) dated HIV seroconverters had a history of symptomatic seroconverting illness. Though baseline neurocognitive function was similar, subjects with a symptomatic seroconverting illness developed clinical neurocognitive impairment significantly more rapidly than their asymptomatic counterparts in a survival analysis model (636 v 1075 days till impaired). CONCLUSION: Symptomatic seroconverting illness predisposes to more rapid neurocognitive impairment.
OBJECTIVES: To establish whether symptomatic seroconverting illness in HIV infectedpeople is associated with more rapid development of neurological impairment. METHODS: 166 HIV infected subjects with a known date of HIV infection enrolled in a longitudinal study of neurocognitive function were stratified by whether or not they had experienced a symptomatic serconverting illness. RESULTS: 29 of 166 (17.5%) dated HIV seroconverters had a history of symptomatic seroconverting illness. Though baseline neurocognitive function was similar, subjects with a symptomatic seroconverting illness developed clinical neurocognitive impairment significantly more rapidly than their asymptomatic counterparts in a survival analysis model (636 v 1075 days till impaired). CONCLUSION: Symptomatic seroconverting illness predisposes to more rapid neurocognitive impairment.
Authors: M T Schechter; K J Craib; T N Le; J S Montaner; B Douglas; P Sestak; B Willoughby; M V O'Shaughnessy Journal: AIDS Date: 1990-03 Impact factor: 4.177
Authors: Prasanta K Dash; Santhi Gorantla; Howard E Gendelman; Jaclyn Knibbe; George P Casale; Edward Makarov; Adrian A Epstein; Harris A Gelbard; Michael D Boska; Larisa Y Poluektova Journal: J Neurosci Date: 2011-03-02 Impact factor: 6.167
Authors: Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price Journal: J Infect Dis Date: 2011-09-01 Impact factor: 5.226
Authors: S Villar del Saz; O Sued; V Falcó; F Agüero; M Crespo; T Pumarola; A Curran; J M Gatell; A Pahissa; J M Miró; E Ribera Journal: J Neurovirol Date: 2008-11 Impact factor: 2.643
Authors: Nancy F Crum-Cianflone; David J Moore; Scott Letendre; Mollie Poehlman Roediger; Lynn Eberly; Amy Weintrob; Anuradha Ganesan; Erica Johnson; Raechel Del Rosario; Brian K Agan; Braden R Hale Journal: Neurology Date: 2013-01-09 Impact factor: 9.910
Authors: Lisa J Madden; Michelle A Zandonatti; Claudia T Flynn; Mike A Taffe; M Cecilia G Marcondes; Jörn E Schmitz; Keith A Reimann; Steven J Henriksen; Howard S Fox Journal: J Neurovirol Date: 2004 Impact factor: 2.643
Authors: Christian Eggers; Gabriele Arendt; Katrin Hahn; Ingo W Husstedt; Matthias Maschke; Eva Neuen-Jacob; Mark Obermann; Thorsten Rosenkranz; Eva Schielke; Elmar Straube Journal: J Neurol Date: 2017-05-31 Impact factor: 4.849